HK1213175A1 - Tspo介导的疾病和/或病症的治疗和/或预防 - Google Patents
Tspo介导的疾病和/或病症的治疗和/或预防 Download PDFInfo
- Publication number
- HK1213175A1 HK1213175A1 HK16101006.2A HK16101006A HK1213175A1 HK 1213175 A1 HK1213175 A1 HK 1213175A1 HK 16101006 A HK16101006 A HK 16101006A HK 1213175 A1 HK1213175 A1 HK 1213175A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- prophylaxis
- disorders
- treatment
- tspo
- mediated diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12007118 | 2012-10-11 | ||
| EP12007118.8 | 2012-10-11 | ||
| PCT/EP2013/003064 WO2014056620A1 (en) | 2012-10-11 | 2013-10-11 | Treatment and/or prophylaxis of tspo mediated diseases and/or disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1213175A1 true HK1213175A1 (zh) | 2016-06-30 |
Family
ID=47073259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16101006.2A HK1213175A1 (zh) | 2012-10-11 | 2013-10-11 | Tspo介导的疾病和/或病症的治疗和/或预防 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9775843B2 (https=) |
| EP (1) | EP2906217A1 (https=) |
| JP (1) | JP2016502503A (https=) |
| CN (1) | CN104994857A (https=) |
| AU (1) | AU2013329832A1 (https=) |
| HK (1) | HK1213175A1 (https=) |
| MX (1) | MX2015004511A (https=) |
| WO (1) | WO2014056620A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| WO2017007756A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc | Hetero-halo inhibitors of histone deacetylase |
| HUE057849T2 (hu) | 2017-01-11 | 2022-06-28 | Alkermes Inc | Hiszton deacetiláz biciklusos gátlói |
| LT3664802T (lt) | 2017-08-07 | 2022-06-27 | Alkermes, Inc. | Bicikliniai histonų deacetilazės inhibitoriai |
| CN111840267A (zh) * | 2020-08-05 | 2020-10-30 | 牡丹江医学院 | 一种治疗小儿口腔黏膜疾病的药物及其制备方法 |
| AU2024282841A1 (en) * | 2023-06-02 | 2025-12-11 | The Johns Hopkins University | Uses of psma-targeting and tspo-targeting compounds for evaluation of injuries in the peripheral nervous system |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| US6756382B2 (en) * | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| DE10239303B4 (de) | 2002-08-27 | 2006-08-03 | Siemens Ag | Energieautark modulierter Backscatter-Transponder |
| US20050197350A1 (en) * | 2003-03-31 | 2005-09-08 | Taisho Pharmaceutical Co., Ltd. | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| SE0302323D0 (sv) * | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| DE602004026095D1 (de) | 2003-11-24 | 2010-04-29 | Pfizer | Chinoloncarbonsäureverbindungen mit 5-ht4-rezeptoragonistischer wirkung |
| EP1912946B1 (en) * | 2005-07-20 | 2009-05-27 | Eli Lilly And Company | Pyridine derivatives as dipeptedyl peptidase inhibitors |
| DE102007044277A1 (de) * | 2007-09-17 | 2009-03-19 | Grünenthal GmbH | Substituierte Nicotinamid-Verbindungen und deren Verwendung in Arzneimitteln |
| CN101392001A (zh) * | 2007-09-21 | 2009-03-25 | 上海恒瑞医药有限公司 | 氨甲酰类衍生物、其制备方法及其在医药上的用途 |
| TWI461197B (zh) | 2009-03-12 | 2014-11-21 | 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier | |
| TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
| JP6023926B2 (ja) * | 2010-02-12 | 2016-11-09 | 株式会社ＡｓｋＡｔ | 認知症治療のための５−ｈｔ４受容体アゴニスト |
| CA2805932A1 (en) | 2010-08-27 | 2012-03-01 | Gruenenthal Gmbh | Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators |
| CA2804824A1 (en) * | 2010-08-27 | 2012-03-01 | Gruenenthal Gmbh | Substituted quinoline-3-carboxamides as kcnq2/3 modulators |
| RU2595894C2 (ru) * | 2010-08-27 | 2016-08-27 | Грюненталь Гмбх | Замещенные 2-окси-хинолин-3-карбоксамиды в качестве модуляторов kcnq2/3 |
| MX342459B (es) * | 2010-08-27 | 2016-09-29 | Grünenthal Gmbh * | 2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas sustituidas, como moduladores de kcnq2/3. |
| US9168259B2 (en) * | 2010-10-20 | 2015-10-27 | Grünenthal GmbH | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators |
| JP5947307B2 (ja) * | 2010-10-20 | 2016-07-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Ｋｃｎｑ２／３調節因子としての置換６−アミノ−ニコチンアミド |
-
2013
- 2013-10-11 CN CN201380064616.9A patent/CN104994857A/zh active Pending
- 2013-10-11 AU AU2013329832A patent/AU2013329832A1/en not_active Abandoned
- 2013-10-11 HK HK16101006.2A patent/HK1213175A1/zh unknown
- 2013-10-11 JP JP2015536018A patent/JP2016502503A/ja active Pending
- 2013-10-11 WO PCT/EP2013/003064 patent/WO2014056620A1/en not_active Ceased
- 2013-10-11 EP EP13776727.3A patent/EP2906217A1/en not_active Ceased
- 2013-10-11 US US14/434,943 patent/US9775843B2/en not_active Expired - Fee Related
- 2013-10-11 MX MX2015004511A patent/MX2015004511A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150290203A1 (en) | 2015-10-15 |
| CN104994857A (zh) | 2015-10-21 |
| MX2015004511A (es) | 2015-07-06 |
| JP2016502503A (ja) | 2016-01-28 |
| AU2013329832A1 (en) | 2015-05-28 |
| US9775843B2 (en) | 2017-10-03 |
| WO2014056620A1 (en) | 2014-04-17 |
| EP2906217A1 (en) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000298A1 (en) | Substituted annulated pyrimidines and triazines, and use thereof | |
| WO2013022991A3 (en) | Methods and compositions relating to p62 for the treatment and prophylaxis of cancer | |
| TN2015000434A1 (en) | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | |
| IL239355A0 (en) | Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders | |
| ZA201500561B (en) | Compositions and treatment for eye diseases and disorders | |
| LT3292875T (lt) | Kompozicijos ir būdai, skirti ligų gydymui | |
| EP2967049A4 (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| AP2014007804A0 (en) | Compositions and methods for the treatment of hepatic diseases and disorders. | |
| SI2838539T1 (sl) | Estrogenski derivati za uporabo pri zdravljenju nevroloških motenj | |
| HK1213175A1 (zh) | Tspo介导的疾病和/或病症的治疗和/或预防 | |
| TN2016000107A1 (en) | Substituted phenylalanine derivatives | |
| GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
| LT2893936T (lt) | Glutarilo histaminas, skirtas ligų, sukeltų (+)rna turinčiais virusais, gydymui ir profilaktikai | |
| MY188071A (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
| PH12015500322B1 (en) | Tris(hetero)arylpyrazoles and use thereof | |
| HK1211239A1 (en) | Treatment regimens | |
| WO2013163562A3 (en) | Compositions and methods for treating ptsd and related diseases | |
| IL237912A0 (en) | History of dihydro-6-azaphenylene for the treatment of the central nervous system, oncological diseases and similar disorders | |
| HK1202868A1 (en) | Carboxamide-substituted heteroaryl-pyrazoles and the use thereof | |
| WO2014056779A8 (de) | Arzneimittel zur prophylaxe und behandlung einer neurodegenerativen erkrankung | |
| PT2686005T (pt) | Composições tópicas compreendendo diamina oxidase para o tratamento ou prevenção de doenças associadas com elevados níveis de histamina que envolvem um aumento na dor | |
| TN2015000523A1 (en) | Substituted benzoxazoles | |
| WO2014082738A8 (en) | Heteroquinoline-3-carboxamides as kcnq2/3 modulators |